Patents by Inventor Ming-Hsin Li

Ming-Hsin Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10834127
    Abstract: An email attempting to perpetrate a business email compromise (BEC) attack is detected based on similarity of the email to a known BEC email and on similarity of the email to a user email that would have been sent by the purported sender of the email. Metadata of the email is extracted and input to a BEC machine learning model to find the known BEC email among BEC email samples. The extracted metadata are also input to a personal user machine learning model of the purported sender to generate the user email.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Trend Micro Incorporated
    Inventors: Che-Fu Yeh, I-Ting Lien, Ming-Lun Li, Shih-Yu Chou, Po-Yuan Teng, Yuan Jiun Tsui, Cheng-Hsin Hsu, Wen-Kwang Tsao, Shih-Han Hsu, Pei-Yin Wu, Jonathan James Oliver
  • Publication number: 20200237938
    Abstract: The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga, 67Ga, 68Ga, 177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
    Type: Application
    Filed: December 11, 2018
    Publication date: July 30, 2020
    Inventors: Ming-Hsin Li, Su-Jung Chen, Ming-Wei Chen, Yuan-Ruei Huang, Shih-Ying Lee, Chun-Fang Feng, Sheng-Nan Lo, Chih-Hsien Chang
  • Publication number: 20200129646
    Abstract: A radioactive labeled long-acting peptide-targeting pharmaceutical and production method, in which the peptide targeted pharmaceutical is firstly dissolved in a solution, followed by labeling the radioactive at a high temperature, and the dosage of the pharmaceutical with radioactive labeling is expected to be reduced and labeling efficiency is improved, and no further purification by filtration is required, which shortens the preparation process and reduces personnel exposure in the working environment. The radioactive labeled long-acting peptide-targeting pharmaceutical can increase the specific binding capacity of tumors and reduce the non-specific accumulation in normal tissues. It can be applied to the field of tumor and nuclear medicine for diagnosis and treatment of tumors and/or tumor metastases with efficacy and precision treatment.
    Type: Application
    Filed: October 31, 2018
    Publication date: April 30, 2020
    Inventors: Ming-Hsin Li, Chih-Hsien Chang, Su-Jung Chen, Shih-Ying Lee, Sheng-Nan Lo, Ming-Wei Chen, Yuan-Ruei Huang, Chun-Fang Feng, Shih-Wei Lo, Cheng-Hui Chuang
  • Publication number: 20200078478
    Abstract: A PSMA targeting peptide derivative for radiotherapy, which is a structural molecule developed for diagnosis or treatment of prostate cancer, as prostate-specific membrane antigen (PSMA) is a protein present on the surface of healthy prostate cells, which is often at a high level of expression on the surface of prostate cancer cells, and the molecular composition of PSMA inhibitor is mainly composed of glutamic acid, urea and lysine, in addition to the linker of the present invention, PSMA inhibitor can be combined with a chelating agent and truncated Evans Blue, which can be labeled with radionuclides Ga-67, Ga-68, In-111, Lu-177, Cu-64 or Y-90, used for image analysis and analysis of human prostate cancer tumor pattern as a new PSMA targeting peptide receptor radionuclide therapy (PRRT), and which has a longer half-life in vivo and is featured by specific binding of PSMA for radiotherapy diagnosis or treatment.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 12, 2020
    Inventors: Ming-Hsin Li, Ming-Wei Chen, Shin-Min Wang, Shih-Wei Lo, Chun-Fang Feng, Cheng-Hui Chuang, Sheng-Nan Lo
  • Patent number: 10571986
    Abstract: A power delivery controller applied to a power converter includes a voltage compensation circuit and a comparator. The voltage compensation circuit is used for generating a compensation reference voltage, receiving a response signal through a universal serial bus type-C cable, and generating a response voltage when an electronic device coupled to the universal serial bus type-C cable generates the response signal corresponding to a Biphase Mark Coding (BMC) signal, wherein the response voltage and the compensation reference voltage have information relative to an internal resistor of the universal serial bus type-C cable. The comparator is used for generating a comparison signal according to the response voltage and the compensation reference voltage, wherein the power converter transmits power to the electronic device according to a specification corresponding to universal serial bus power delivery (USB-PD) after the comparator generates the comparison signal.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 25, 2020
    Assignee: Leadtrend Technology Corp.
    Inventors: Ming-Hung Chien, Chun-Hsin Li, Ching-Tsan Lee
  • Publication number: 20200029909
    Abstract: There is provided a system architecture including a PPG hardware module and a MEMS hardware module. The PPG hardware module processes PPG raw data, which is generally composed of analog signals or digital signals. The PPG hardware module filters the raw data for later digital calculation to, for example, find out frequency signals with higher peak values. The PPG hardware module then outputs the selected frequency signals to an MCU for heart rate calculation. The MEMS hardware module receives MEMS raw data from a motion detector made of MEMS elements. The MEMS raw data represents motion status of a user that could possibly affect the heart rate determination result. The MEMS hardware module filters the raw data for later digital calculation to find out frequency signals with higher peak values caused by motion.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 30, 2020
    Inventors: REN-HAU GU, YEN-MIN CHANG, MING-CHANG LI, CHIH-HSIN LIN
  • Patent number: 10507250
    Abstract: Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through —CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 17, 2019
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Patent number: 10478128
    Abstract: There is provided a system architecture including a PPG hardware module and a MEMS hardware module. The PPG hardware module processes PPG raw data, which is generally composed of analog signals or digital signals. The PPG hardware module filters the raw data for later digital calculation to, for example, find out frequency signals with higher peak values. The PPG hardware module then outputs the selected frequency signals to an MCU for heart rate calculation. The MEMS hardware module receives MEMS raw data from a motion detector made of MEMS elements. The MEMS raw data represents motion status of a user that could possibly affect the heart rate determination result. The MEMS hardware module filters the raw data for later digital calculation to find out frequency signals with higher peak values caused by motion.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 19, 2019
    Assignee: PIXART IMAGING INC.
    Inventors: Ren-Hau Gu, Yen-Min Chang, Ming-Chang Li, Chih-Hsin Lin
  • Publication number: 20190076552
    Abstract: Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through —CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.
    Type: Application
    Filed: September 8, 2017
    Publication date: March 14, 2019
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Patent number: 10005727
    Abstract: The present invention relates to a group of compounds for nuclear medicine imaging through F-18 labeled histone acetylation inhibitors (HDACi) of indole or indoline benzoyl amine and its derivatives, and provides a series of nuclear medicine imaging agents that bind with HDAC overexpression in vivo for diagnosis of malignant tumors discovered in the nuclear medicine imaging tracing.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 26, 2018
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL EXECUTIVE YUAN
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Publication number: 20180099933
    Abstract: The present invention relates to a group of compounds for nuclear medicine imaging through F-18 labeled histone acetylation inhibitors (HDACi) of indole or indoline benzoyl amine and its derivatives, and provides a series of nuclear medicine imaging agents that bind with HDAC overexpression in vivo for diagnosis of malignant tumors discovered in the nuclear medicine imaging tracing.
    Type: Application
    Filed: October 6, 2016
    Publication date: April 12, 2018
    Inventors: MING-HSIN LI, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Publication number: 20170319723
    Abstract: Disclosed herein is a radioimmune complex comprising an epidermal growth factor receptor (EGFR)-targeted antibody and a radioactive isotope of rhenium labeled thereon. The EGFR-targeted antibody is cetuximab or panitumumab.
    Type: Application
    Filed: May 3, 2017
    Publication date: November 9, 2017
    Inventors: WAN-I KUO, KAI-HUNG CHENG, YI-SHU HUANG, SHENG-NAN LO, YA-JEN CHANG, TSUNG-TSE WU, WEI-CHUAN HSU, MING-HSIN LI, CHIH-HSIEN CHANG
  • Patent number: 9707521
    Abstract: An automated test apparatus for risk and integrity testing for pharmaceutical filtration membranes, including at least the following components: a liquid injection inlet, a pump, a fluid pressure gauge, a gas pressure gauge, a plurality of solenoid valves, a plurality of membranes, a gas pressure regulator valve, a pharmaceutical product bottle, and a bubble generation bottle. The automated test apparatus of the present invention is controlled by computer software in connection with an automatic pharmaceutical synthesis apparatus for automated testing. In use of the automated test apparatus of the present invention, it needs only to start the operating system of the automated test apparatus for membrane risk and integrity test after the completion of the automatic pharmaceutical synthesis. The membrane risk and integrity test can be accomplished in a short time by measuring pressures of gas and liquid with pressure gauges deposed online concurrently.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: July 18, 2017
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Ming-Hsin Li, Shu-Pei Chiu, Chih-Hsien Chang, Te-Wei Lee
  • Publication number: 20170110211
    Abstract: A method to produce a high-purity Zr-89 on a solid target through physical irradiation and measurement by selecting a target Barn value of the cross-sectional area of nuclear reaction, drawing a horizontal line to intersect at two points on the function diagram curve and drawing a vertical line downward from each of the two points intersecting at X-axis to obtain incident energy values at the two intersecting points on the X-axis, and followed by plotting an attenuation function diagram curve of penetration depth versus incident energy of Y-89(p,n)Zr-89, selecting an attenuation function diagram curve and a minimum attenuation position of the selected attenuation function diagram curve in correspondence to the incident energy in the interval of incident energy absorption range to obtain an optimal plating thickness value on the solid target.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 20, 2017
    Inventors: Ming-Hsin LI, Ting-Shien DUH, Wuu-Jyh LIN, Han-Hsiang CHU
  • Patent number: 9603950
    Abstract: A method of synthesizing a compound of imaging agent with HDAC (histone deacetylase) inhibitor consists of two parts, the first part of the method is to provide the inhibitor of HDAC with a compound of imaging agent that includes HDAC inhibitor BNL-26 (C22H23N3O) and its analogs to be labeled with radionuclide F-18, producing a series of new nuclear medicine tracers: BNL-26-CH2CH218F, BNL-26a-CH2CH218FF, BNL-26b-CH2CH218F, BNL-26c-CH2CH218F and BNL-26d-CH2CH218F. These nuclear medicine with imaging agents can be used as a tracer in vivo binding to over-expression HDAC and produce a HDAC nuclear medicine imaging effect to serve for clinical diagnosis. The second part of the method is to provide a slightly adjusted a structural framework of BNL-26 and use pyridine to substitute the benzene ring of the BNL-26 structure, and then synthesize with other substituent to produce a series of additional 30 more HDAC inhibitors, named from Iner-1 to Iner-30 compounds.
    Type: Grant
    Filed: October 25, 2015
    Date of Patent: March 28, 2017
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Han-Hsiang Chu
  • Patent number: 9468608
    Abstract: The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: October 18, 2016
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Wuu-Jyh Lin, Ting-Shien Duh, Wei-Ming Li, Ming-Hsin Li
  • Publication number: 20160113884
    Abstract: The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 28, 2016
    Inventors: Wuu-Jyh Lin, Ting-Shien Duh, Wei-Ming Li, Ming-Hsin Li
  • Patent number: 9277192
    Abstract: The present invention relates to a system of real time micro hot cell image control for radiopharmaceutical automatic synthesizing apparatus including at least one CCD camera, a plurality of radioactivity detector, a logic control device, a computer interface control device. The plurality of radioactivity detector are connected to the logic control device, and the logic control device sends a corresponding location code to the computer interface control device when the detected radioactivity value is greater than the threshold value for selecting a nearest CCD camera and sending the taken image of the location to the computer interface control device for monitoring whether the automatic production line of radiopharmaceuticals is kept in normal operation.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: March 1, 2016
    Assignee: INSTITUTE of NUCLEAR ENERGY RESEARCH
    Inventor: Ming-Hsin Li
  • Patent number: 9266084
    Abstract: The invention provides an automatic synthesizer apparatus and method for producing radiopharmaceutical tumor imaging agent Gallium-68-DOTATATE with one button control process to effectively isolate the medication in vials from the contamination of environment and manual operations, saving the costs of investment in production with alleviation of the critical standard required for the environmental equipments to be used for production.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: February 23, 2016
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Ming-Hsin Li, Hsin-Han Hsieh
  • Publication number: 20150374859
    Abstract: A synthesis method of labeling histone deacetylase inhibitor (HDAC inhibitors) SC027 with Gallium-67 or Gallium-68 radionuclide, wherein a labeled precursor DOTA-SC027 which comprises DOTA-NHS-ester (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-N-hydroxysuccinimide-ester) and HDACi-SC027 is prepared for the synthesis to label HDACi-SC027 with Gallium-67 or Gallium-68 radionuclide for producing imaging tracers for tracking the HDACi.
    Type: Application
    Filed: June 25, 2014
    Publication date: December 31, 2015
    Inventor: Ming-Hsin Li